Novo Nordisk A/S : Q2 2020 conference call presentation

Novo Nordisk

• a focused healthcare company

Investor presentation

First six months of 2020

2

Investor presentation

First six months of 2020

Agenda

Highlights COVID-19 update Sales update R&D update Financials & outlook Strategic aspirations 2025

3

Investor presentation

First six months of 2020

Novo Nordisk®

Forward-looking statements

Novo Nordisk's reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation as well as the company's statutory Annual Report 2019 and Form 20-F, which are both expected to be filed with the SEC in February 2020 in continuation of the publication of the Annual Report 2019, and written information released, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain forward-looking statements. Words such as 'believe', 'expect', 'may', 'will', 'plan', 'strategy', 'prospect', 'foresee', 'estimate', 'project', 'anticipate', 'can', 'intend', 'target' and other words and terms of similar meaning in connection with any discussion of future operating or financial performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:

• Statements of targets, plans, objectives or goals for future operations, including those related to Novo Nordisk's products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto,
• Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures,
• Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings, and
• Statements regarding the assumptions underlying or relating to such statements.

These statements are based on current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. Novo Nordisk cautions that a number of important factors, including those described in this presentation, could cause actual results to differ materially from those contemplated in any forward-looking statements.

Factors that may affect future results include, but are not limited to, global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, product recalls, unexpected contract breaches or terminations, government-mandated or market-driven price decreases for Novo Nordisk's products, introduction of competing products, reliance on information technology, Novo Nordisk's ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, failure to recruit and retain the right employees, and failure to maintain a culture of compliance.

For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk's results or the accuracy of forward-looking statements in this presentation, reference is made to the overview of risk factors in 'Managing risks to protect value' on pp 33-35 of the Annual Report 2019.

Unless required by law, Novo Nordisk is under no duty and undertakes no obligation to update or revise any forward-looking statement after the distribution of this presentation, whether as a result of new information, future events or otherwise.

Important drug information

• Victoza® is approved for the management of type 2 diabetes only
• Saxenda® is approved in the USA and the EU for the treatment of obesity only

4 Investor presentation First six months of 2020

Strategic aspirations for 2025

-Highlights first six months of 2020

Adding value to society:

• Launch of new social responsibility strategy to defeat diabetes
• Participation in antimicrobial resistance initiative
• Expansion of US affordability offerings
• Societal contributions during COVID-19 pandemic

Sourcing of green power at all US operations and 100% renewable power across all production sites

39% reduction in CO2 emissions compared to the first half of 2019 due to use of renewable energy and lower travel activities

Diabetes sales increased by 7%:

• Value market share leadership expanded by 0.8%-points to 29.0%
• Sales of GLP-1 increased by 28% driven by continued performance of Ozempic®

Obesity sales increased by 9% to DKK 2.9 billion

Biopharm sales increased by 6% driven by IO and NAO

Novo Nordisk®

Diabetes:

• Insulin icodec phase 2 trial successfully completed
• Rybelsus® approved in the EU, the UK and Japan
  Obesity:
• Successful completion of obesity trials:
• • Semaglutide obesity phase 3 programme
  • AM833 monotherapy phase 2 trial
  • AM833 in combination with semaglutide phase 1 trial
    Other serious chronic disease:
• Agreement to acquire of Corvidia Therapeutics
• Positive phase 2 data for semaglutide in NASH

Sales increased by 7%, to DKK 63.9 billion

• 12% and 1% growth in IO and NAO, respectively
• In the US, 46% of sales transformed to products launched since 2015

Operating profit increased by 8% to DKK 30.1 billion

• Productivity improvement and improved admin-to-sales ratio

An interim dividend of DKK 3.25 for each Novo Nordisk A and B share of DKK 0.20, which will be paid in August 2020

The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth

Note: Unless otherwise specified growth rates are at constant exchange rates; FDA: Food and Drug Administration; EMA: European Medicines Agency; AGHD: Adult growth hormone disease; NASH: Non-alcoholic steatohepatitis; New-generation insulin: Tresiba®, Xultophy®, Ryzodeg®, Fiasp®

5

Investor presentation

First six months of 2020

Novo Nordisk®

Novo Nordisk response to COVID-19 pandemic

Novo Nordisk status across the value chain

• All manufacturing sites are operational
• Medicines available to patients worldwide

Production

Gradual 'return to normal' across regions

•	China approaching pre-COVID-19 activity level
•	EMEA and RoW cautiously re-opening
•	~60% of affiliates with some face-to-face

R&D

Commercial

• Continuation of on-going clinical trials
• Trial recruitment negatively impacted, but gradually improving
• It is now possible to initiate new trials in certain countries
• Majority of Novo Nordisk medicines used for chronic treatment
• Fewer patients initiating new treatment
• Increased stocking partly driven by increased Rx duration

International

Operations

North America Operations

	interactions with doctors
•	US status varies substantially per state
•	Nearly 100% of US sales force partially back in
	the field

6

Investor presentation

First six months of 2020

Novo Nordisk®

COVID-19 negatively impacted new patient initiations in the US in the first half of 2020, but there are signs of gradual recovery

US insulin indexed NBRx development

US GLP-1 indexed NBRx development

US Saxenda® indexed NBRx development

Index 140

120

100

80

60

40

Feb

2020

Insulin

13 March, lockdown implemented in most states

84

Jul

2020

Index		13 March, lockdown			GLP-1
140
		implemented in most states
120
100
80								81
60
40
							Jul
Feb	2/1/20	3/1/20	4/1/20	5/1/20	6/1/20
1/1/20	7/1/20
2020							2020

Index 140

120

100

80

60

40

Feb

2020

Saxenda®

13 March, lockdown implemented in most states

86

Jul

2020

Note: index based on average weekly observations in January 2020; "Insulin" consists of both long-acting and fast-acting insulin

Source: US weekly 1x1 NBRx (Xponent, Diabetes 10 July 2020, Obesity 10 July 2020)

7

Investor presentation

First six months of 2020

Novo Nordisk®

Sales growth of 7% at CER, driven by solid sales growth in International Operations

			Reported sales split for the first half of 2020
DKK		Insulin			GLP-1			Other diabetes		Obesity		Biopharm
billion		Growth at CER
40
		12%
35
																			1%
30								International Operations
25
20								11%
15
															14%
10												12%
5
0
		IO				EMEA			China		RoW				NAO

Growth drivers for the first half of 2020

International Operations sales growth of 12% at CER

• Sales growth driven by all areas
• Growth was impacted by COVID-19-related stocking and other timing events, partially offset by fewer patients initiating treatment

North America Operations sales increased by 1% at CER

• Sales growth positively impacted by first quarter 2020 surge in demand
• Surge in demand largely offset by fewer patients initiating treatment and less use of NovoSeven® due to the lockdown

IO: International Operations; EMEA: Europe, Middle East, and Africa; China: Mainland China, Hong Kong, Taiwan; RoW: Rest of World; NAO: North America Operations

8

Investor presentation

First six months of 2020

Novo Nordisk®

Sales growth driven by GLP-1, Obesity, and Biopharm

Added reported sales and growth per therapy area and

operational unit at CER

DKK				North America					International Operations
billion				Growth at CER
6
5		7%			-3%			28%			9%			6%
4
								37%
3		12%
2
								25%
															10%
1						10%							8%
	1%
0
-1													9%			1%
					-23%
-2
-3		Total1		Insulin	GLP-1	Obesity	Biopharm

Growth drivers for the first half of 2020

Expanding global diabetes value market leadership by 0.8%-pointsto

29.0%

• Global insulin volume market share increased by 0.3%-points to
  46.7%
• GLP-1market leadership expands by 2.7%-points to 49.1% value market share

Global obesity value market share of 60.5%

Biopharm sales increased by 6% at CER, driven by Norditropin®

1 'Other diabetes' is included in Total CER: Constant exchange rates Source: IQVIA MAT, Jun 2020

9

Investor presentation

First six months of 2020

Novo Nordisk®

Early Rybelsus® uptake further supports GLP-1 NBRx and TRx market leadership in the US

USA GLP-1 NBRx market share

Weekly
NBRx	Ozempic®	Rybelsus®	dulaglutide	NN GLP-1	Victoza®
share
70%
60%					58.3%
50%	50.3%
40%	41.2%				35.6%
30%	30.8%				34.9%
20%	19.5%
				12.4%
10%
				11.0%
0%	Jul				Jul
	2018				2020

USA GLP-1 TRx market size and market share

Weekly
TRx	Ozempic®	Rybelsus®	dulaglutide	NN GLP-1	Victoza®
share
60%		Class growth around 30%
50%	45.9%				49.2%
40%	44.1%				44.3%
30%	32.2%
				26.1%
20%					20.3%
10%	12.0%
0%					2.8%
Jul				Jul
	2018				2020

Source: NBRx-IQVIA National LRx Weekly, Jul 2020

NBRx: New-to-brand prescriptions

10

Investor presentation

First six months of 2020

Novo Nordisk®

Novo Nordisk is increasing its diabetes market share in IO, driven by insulin and GLP-1 growth

Diabetes value market share and share of growth in IO

Reported Insulin and GLP-1 sales, growth, and share of IO growth

Market	NN market share	NN share of growth
share
30%
25%		25.8%
20%		22.3%
15%		Market share
	+0.4-pp vs. 2019
10%

5%

0%

May	May
2018	2020

Source: IQVIA moving annual total, spot rate, May 2020

IO: International operations; NN: Novo Nordisk; pp: Percentage points

IO: International Operations; EMEA: Europe, Middle East, and Africa; China: Mainland China, Hong Kong, Taiwan; ROW: Rest of World

DKK				Insulin		GLP-1	Growth at		Share of
billion
						CER		Growth
25
	12%
20	51%

15

10 11% 37%

						12%
		39%
5								14%
			39%
										42%
0								18%
IO	EMEA		China		ROW

11

Investor presentation

First six months of 2020

Novo Nordisk®

Saxenda® sales growth of 9% is impacted by fewer patient initiations

Reported sales split in operational units

Novo Nordisk remains global market leader

DKK		NAO	IO		Market Share		Growth at CER	Market
billion									9%2	Share
1.6										80%
						42%1
1.2				51%1					61%	60%
0.8	64%1									40%
0.4											20%
0											0%
	Q3	Q4	Q1	Q2	Q3	Q4 Q1	Q2	Q3	Q4	Q1 Q2
	2017		2018		2019		2020

1. Year growth at CER
2. Year-to-dategrowth at CER

EMEA: Europe, Middle East, and Africa

Note: Sales growth at constant exchange rates

Global

IO

NAO

• Novo Nordisk expands market leadership to 61% value market share from 52%
• Saxenda® is launched in 48 countries
• Sales growth impacted by fewer patients initiating treatment due to COVID-19
• Sales growth of 8% driven by EMEA and Rest of World
• Novo Nordisk currently has a value market share of 38% in the obesity market
• Sales growth of 9% driven by both the USA and Canada
• Novo Nordisk currently has a value market share of 72% in the obesity market

12

Investor presentation

First six months of 2020

Novo Nordisk®

Biopharm sales growth of 6%, driven by Norditropin®

Reported Biopharm sales across products

DKK			Growth at CER
billion	6%	-5%	-2%	42%	18%
0.8
0.6
0.4			Haemophilia
0.2
0.0
-0.2		Novo-	Novo-	Other	Nordi-
	Total	haemo-
	Seven®	Eight®	tropin®
-0.4		philia®

Biopharm sales driven by global commercial execution

Biopharm sales growth driven by:

• 10% growth in International Operations
• 1% growth in North America Operations
• Impact from timing of shipments, changes in inventories, and COVID-19-related stocking

Haemophilia sales decreased by 1% driven by:

• Decreased NovoSeven® sales, partly reflecting reduced bleedings and elective surgeries due to COVID-19 lockdowns.

Norditropin® sales increased by 18% at CER

• Novo Nordisk is the leading company in the global human growth disorder market with a value market share of 34.2%

Note: ''Other haemophilia' includes the new products Esperoct® and Refixia® as well as NovoThirteen®

Note: Sales growth at constant exchange rates

13

Investor presentation

First six months of 2020

Novo Nordisk®

Across the STEP 1, 3, and 4 trials, a weight loss of 16.9% to 18.2% was reported for people treated with semaglutide 2.4 mg

	STEP 1	STEP 3	STEP 4		STEP 2
	Weight	Weight management	Sustained weight management	Weight management with
	management	with IBT	From initiation	From randomisation	T2DM
Baseline body			to 68 weeks	to 68 weeks1
105.3	105.8	107.2	96.1	99.8
weight (kg)

	10	Sema	Placebo	Sema	IBT	Sema	Placebo	Sema	Placebo	Sema	Placebo
				+ IBT					6.5
from baseline	5
0
-5		-2.4								-3.1
BW(%)				-5.0		-5.2
	-10							-8.8*		-10.6*
Change	in
	-15
	-20	-16.9*		-17.6*		-18.2 *

1 The primary endpoint was measured as the change in weight from randomisation (after a 20-weekrun-in) to week 68.

*Statistically significant, based on the trial product estimand (secondary statistical approach): treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies

IBT: Intensive behavioural therapy; Sema: Semaglutide; BW: Body weight; T2D: Type 2 diabetes

14

Investor presentation

First six months of 2020

Novo Nordisk®

The AM833 phase 2 monotherapy trial and phase 1 combination with semaglutide trial decreased weight by 10.8% and 17.1%

Weight loss for AM833 plus lifestyle intervention1

• change in body weight

0			Mean baseline: 107.4 kg
-4
-8
				- 10.8%
-12
0		Weeks		26
AM833	AM833	AM833	AM833	AM833
0.3mg	0.6mg	1.2mg	2.4mg	4.5mg
Placebo	Lira
	3.0mg

Weight loss for AM833 and semaglutide in phase 12

• change in body weight

0		Mean baseline: 95.1 kg
-4
-8		- 9.5%
-12
-16		- 17.1%
-20
0	Weeks	20

AM833 0.3 mg	AM833 0.16 mg	AM833 0.6 mg	AM833 1.2 mg	AM833 2.4 mg
sema 2.4 mg	sema 2.4 mg	sema 2.4 mg	sema 2.4 mg	sema 2.4 mg
sema 2.4 mg

1. Lifestyle intervention is defined as counselling for a reduced-calorie diet and increased physical activity. Data is based on the trial product estimand: treatment effect if all people adhered to treatment and did not initiate other anti-obesity therapies
2. Data are observed means, 20 week phase 1b trial dosing increments with semaglutide and AM833 once-weekly with a 16 week dose-escalation regimen. Data is based on the trial product estimand.

15

Investor presentation

First six months of 2020

Novo Nordisk®

R&D milestones for 2020 and Q1 2021

Clinical milestones1

Regulatory milestones1

Project

Q2 2020

Q3 2020

Q4 2020

Q1 2021

Diabetes

Ozempic®

SUSTAIN FORTE -

SUSTAIN FORTE -

Phase 3 results

US/EU submission

Xultophy®

China submission

Icodec

Phase 3 initiation

Rybelsus®

 EU commission decision

 Japan PMDA decision

Obesity

Semaglutide Obesity

Phase 3 results

US/EU submission

AM833 (Amylin)

Phase 2 results

AM833 + Semaglutide

Phase 1 results

Obesity projects

Phase 1 results (terminated)

Biopharm

Somapacitan (AGHD)

US/EU decision

Japan decision

Other serious chronic

Semaglutide NASH

Phase 2 results

Phase 2 results (PoC, Gilead)

diseases

PCSK9i	Phase 1 results
Staten	Phase 1 initiation
Ziltivekimab	Phase 2 results

1 Expected to be published in the given quarter or in the subsequent quarterly company announcement; Note: Trial initiations could be impacted by COVID-19 status; Concizumab phase 2 and phase 3 clinical trials paused; Timeline for the FGF-21 in NASH project has moved

Sema: Semaglutide; GIP: Gastric inhibitory polypeptide; EU: European Union; JP PMDA: Japanese Pharmaceutical and Medical Devices Agency; OW: Once-weekly; AGHD: Adult growth hormone deficiency; PoC: Proof of Concept; NASH: Non- alcoholic steatohepatitis

16

Investor presentation

First six months of 2020

Novo Nordisk®

Financial results - First six months of 2020

	First six	First six	Change	Change
	months of	months	(reported)	(CER)
In DKK million	2020	of 2019
Sales	63,881	59,327	8%	7%
Gross profit	53,723	49,746	8%
Gross margin	84.1%	83.9%
Sales and distribution costs	14,988	14,526	3%	3%
Percentage of sales	23.5%	24.5%
Research and development costs	7,068	6,235	13%	13%
Percentage of sales	11.1%	10.5%
Administration costs	1,754	1,763	(1%)	0%
Percentage of sales	2.7%	3.0%
Other operating income, net	227	469	(52%)
Operating profit	30,140	27,691	9%	8%
Operating margin	47.2%	46.7%
Financial items (net)	(1,703)	(2,324)	(27%)
Profit before income tax	28,437	25,367	12%
Income taxes	5,915	5,327	11%
Effective tax rate	20.8%	21.0%
Net profit	22,522	20,040	12%
Diluted earnings per share (DKK)	9.58	8.39	14%

CER: Constant exchange rates

17

Investor presentation

First six months of 2020

Novo Nordisk®

Currency developments in the first six months of 2020

currencies	5%			Avg. H1 2020 vs. H1 2019			Exp. avg FY 20201vs. FY 2019
3%
1%
Hedged	-1%
-3%
	-5%				USD/DKK	CNY/DKK	JPY/DKK	CAD/DKK	GBP/DKK
currencies	10%
-10%
hedged-	0%
-20%
Non	-30%
	-40%			RUB/DKK	INR/DKK	ARS/DKK	BRL/DKK	TRY/DKK

Hedged	H1 2019	H1 2020	Spot rate2	Impact of a 5%	Hedging
currencies	avg.	avg.		move4	(months)
USD2	661	678	635	1,850	10
CNY2	97	96	91	400	65
JPY2	6.0	6.3	6.0	150	12
CAD2	495	497	473	130	9
GBP2	855	855	827	100	10
Non-hedged	H1 2019	H1 2020	Spot rate3
currencies	avg.	avg.
ARS2	0.2	0.1	0.1
TRY2	118	105	91
INR2	9.4	9.2	8.4
RUB2	10.1	9.8	8.6
BRL2	172	140	121

1. Year-to-daterealised data and remainder expected flat currency development based on the spot rate as of 3 August 2020; 2 DKK per 100; 3 Spot rate as of 3 August 2020;

1. Impact on operating profit in the next 12 months of a 5% immediate currency move. DKK million per annum; 5 Chinese Yuan traded offshore (CNH) Note: Operating profit impact of one of the non-hedged currencies appreciating 5% is in the range of DKK +10 to +50 million

18

Investor presentation

First six months of 2020

Novo Nordisk®

Financial outlook for 2020

Expectations	Expectations
6 August 2020	6 May 2020

Sales growth - at CER Sales growth - reported Operating profit growth - at CER

Operating profit growth - reported Financial items (net)

Effective tax rate

Free cash flow

3% to 6%	3% to 6%
Around 2 percentage points lower	Around 1 percentage point higher
2% to 5%	1% to 5%
Around 3 percentage points lower	Around 1 percentage point higher
Loss of around DKK 1.2 billion	Loss of around DKK 2.5 billion
20% to 22%	20% to 22%
DKK 33 to 38 billion	DKK 36 to 41 billion

The financial outlook is based on an assumption of a continuation of the current business environment and given the current scope of business activities and has been prepared assuming that currency exchange rates remain at the level as of 3 Aug 2020

19 Investor presentation First six months of 2020

Strategic aspirations for 2025 -Milestones expected for 2020

Launch of new social responsibility strategy to defeat diabetes

Expansion of the US affordability offerings Utilise solar energy power across all US operations 100% renewable power in 2020 for all production sites

Expand diabetes market leadership led by launches and penetration of Ozempic®, Rybelsus®, and new-generationinsulin

Strengthen Obesity leadership with continued global rollout and penetration of Saxenda®

Continued launches of key Biopharm products Refixia® and

Esperoct® support sustained growth outlook

Novo Nordisk®

Diabetes:

• Sema FORTE phase 3 results due Q4 2020
• Insulin icodec phase 3 initiation in Q4 2020

Obesity:

• Semaglutide obesity phase 3 successfully completed
• AM833 monotherapy and in combination with semaglutide phase 2 successfully completed

Biopharm:

• Mim8 phase 1/2 initiated
• Somapacitan regulatory feedback from the FDA/EMA for the treatment of AGHD

Other serious chronic diseases:

• Phase 2 readouts from two NASH trials
• Signed an agreement for the acquisition of Corvidia

Sales growth is still expected to be 3-6% (reported: around 2 percentage point lower)

Operating profit growth is now expected to be 2-5%(reported: around 3 percentage points lower)

Free cash flow is now expected to be in the range of DKK 33-38 billion

DKK 17 billion share repurchase programme

The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth

Note: Outlook as of 6 May 2020; Unless otherwise specified growth rates are at constant exchange rates; FDA: Food and Drug Administration; EMA: European Medicines Agency; AGHD: Adult growth hormone disease; NASH: Non-alcoholic steatohepatitis; New-

generation insulin: Tresiba®, Xultophy®, Ryzodeg®, Fiasp®

20

Investor presentation

First six months of 2020

Novo Nordisk®

Investor contact information

Share information

Novo Nordisk's B shares are listed on the stock exchange in Copenhagen under the symbol 'NOVO B'. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'.

For further company information, visit Novo Nordisk on: www.novonordisk.com

Upcoming events

30 Oct 2020 Financial statement for the first nine months of 2020

03 Feb 2021 Financial statement for the full year of 2020

Investor Relations contacts

Novo Nordisk A/S

Investor Relations

Novo Allé

DK-2880 Bagsværd

Daniel Muusmann Bohsen	[phone]	[e-mail]
Valdemar Borum Svarrer	[phone]	[e-mail]
Ann Søndermølle Rendbæk	[phone]	[e-mail]
Mark Joseph Root	[phone]	[e-mail]
Kristoffer Due Berg (USA)	[phone]	[e-mail]